Table 1.

MIC₅₀s of the BZT compounds against human pathogenic fungi^a

Strain	MIC50 (μg/ml)
	DFD-VI-15	BD-I-186	DFD-V-49	DFD-V-66	Fluconazole	Micafungin	AmpB
C. albicans CAF2	1.6	1.6	1.6	1.6	0.2	0.016	0.25
C. glabrata RC-201	1.6	0.8	3.2	1.6	3.2	0.016	0.25
C. tropicalis RC-501	1.6	1.6	3.2	3.2	16	0.016	0.5
C. parapsilosis RC-601	1.6	0.8	3.2	3.2	0.4	0.5	0.25
C. lusitaniae RC-301	1.6	0.8	1.6	3.2	3.2	0.03	0.25
C. guilliermondii RC-401	1.6	1.6	3.2	3.2	6.4	0.5	0.25
C. apicola RC-701	1.6	3.2	3.2	3.2	0.2	0.016	0.25
A. fumigatus AF-294	12.5	6.4	6.4	3.2	16	1.0	0.5
C. neoformans H99	1.6	1.6	6.4	3.2	>64	>2	>10
C. neoformans JEC-21	1.6	0.8	6.4	1.6	>64	>2	>10

^aMIC₅₀s (μg/ml) of the BZT compounds are shown against a panel of human pathogenic fungi. The antifungal activities of the compounds were also compared to those of fluconazole, micafungin, and amphotericin B (AmpB) against the same strains. Results for fungicidal compounds are indicated in bold numbers. (Fungicidal, MFC/MIC₅₀ ≤4; fungistatic, MFC/MIC₅₀ >4.) Data are shown as averages of results from five experiments.